H. Lundbeck A/S

lundbeck.com

Total trials

222

Active

14

Phase 3

82

Total enrollment

58,258

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 8 of 8 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Eptinezumab16
Amlenetug1
Lu AF289967
Lu AG139092
Lu AG092226
Lu AF824223
Lu AG225152
Lu AH695931

Next readouts

  • 2023-11-16
  • 2026-01-16
  • 2026-03-17
  • 2026-06-05
  • 2026-09-05
  • 2026-09-15
  • 2026-09-30
  • 2026-12-01
  • 2027-05-31
  • 2027-07-06

Top conditions

  • Healthy34
  • Major Depressive Disorder29
  • Schizophrenia28
  • Migraine15
  • Alzheimer's Disease10
  • Primary Insomnia10
  • Healthy Participants9
  • Parkinson Disease8

Frequently asked questions about H. Lundbeck A/S

How many clinical trials does H. Lundbeck A/S have on ClinicalTrials.gov?
H. Lundbeck A/S is listed as the lead sponsor on 222 clinical trials in ClinicalTrials.gov, 14 of which are currently active (recruiting, enrolling, or ongoing).
How many of H. Lundbeck A/S's trials are in Phase 3?
82 of H. Lundbeck A/S's trials are in Phase 3, spread across 8 active drug programs.
What therapeutic areas does H. Lundbeck A/S focus on?
H. Lundbeck A/S's most-studied conditions on ClinicalTrials.gov are Healthy, Major Depressive Disorder, Schizophrenia, Migraine, Alzheimer's Disease.
When are H. Lundbeck A/S's next clinical trial readouts?
H. Lundbeck A/S has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study of Lu AF82422 in Participants With Multiple System Atrophy”, expected around 2023-11-16.